Remove Clinical Pharmacology Remove Drug Development Remove Presentation
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent). For use as endpoints, biomarkers must be correlated to a valid clinical outcome.

article thumbnail

Optimized 505(b)(1) and 505(b)(2) Clinical Pharmacology Programs to Accelerate Drug Development

The Premier Consulting Blog

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Shaping drug development success: how does artwork play a role?

Drug Target Review

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

article thumbnail

Biomarker identification in the realm of rare diseases

Drug Target Review

However, some biomarkers may only be present in a minority of patients, requiring a large patient population to identify such markers. How do AI-enhanced approaches accelerate the drug development process for rare diseases? Not all biomarkers have a limited prevalence.

Disease 59
article thumbnail

Top 10 Life Science Resources for Summer 2024

Alta Sciences

Watch the poster presentation. TOP MANUFACTURING AND ANALYTICAL SCIENTIFIC RESOURCES Podcast: Successful Manufacturing of Clinical Trial Supply Join our formulation and pharmacy experts as they share insider secrets for overcoming clinical trial challenges and resolving issues that could impact your drug development program's timeline.

Science 52
article thumbnail

Top 10 Life Science Resources

Alta Sciences

Podcast : FDA Guidance for Industry Psychedelic Drugs Extensively studied for potential therapeutic efficacy, psychedelic drug development comes with its own set of clinical development requirements. Watch the video. Listen here. The Altascientist : Issue No. Read or listen now. Want to see more?

Science 52
article thumbnail

CMC Considerations for Pre-IND Meetings

The Premier Consulting Blog

An unintended change in the form of the drug substance may affect drug product quality attributes and should be addressed at the pre-IND meeting. If an excipient is not listed in the IID or is present in levels exceeding the IID, justification of the use level is required and may involve non-clinical subject matter experts.